Entera Bio (ENTX) Stock Insights

ENTX price $3.19 +0.07 +2.24%

Ticker
ENTX
Price
$3.19
Change
+0.07 +2.24%
Market cap ?
$554.81M
P/E ?
-8.94
Dividend yield ?
0.00%
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
67
Value
57
Quality
44
Growth
100

Stocklytics score rationale: value 57, quality 44, growth 100.

Financials

2016201720182019202020212022202320242025
$0.00$0.00$500,000.00$236,000.00$365,000.00$571,000.00$134,000.00$0.00$181,000.00$42,000.00

Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.

Fair value

ENTX fair value Not meaningful. Price $3.19.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price.

Fair value blends a 10-year DCF and an industry P/E: the average of the DCF value and an earnings value from next-twelve-months EPS times the industry median P/E. How we calculate it →

Not meaningful

Compare ENTX

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-11-13—-0.07——
2026-08-07-0.14-0.08——
2026-05-08-0.07-0.08——
2026-03-27-0.07-0.09——
2025-11-14-0.07-0.09——
2025-08-08-0.06-0.11——
2025-05-09-0.06-0.0742.00K—
2025-03-28-0.06-0.0882.00K40.00K
2024-11-08-0.08-0.0542.00K40.00K
2024-08-09-0.06-0.0657.00K—
2024-05-10-0.05-0.06——
2024-03-08-0.07-0.084.48M—
2023-11-14-0.08-0.09——
2023-08-11-0.08-0.0714.00K—
2023-05-05-0.08-0.1213.00K100.00K
2023-03-27-0.11-0.1114.00K50.00K
2022-11-10-0.11-0.168.00K70.00K
2022-08-11-0.11-0.1344.00K100.00K
2022-05-12-0.13-0.1668.00K178.50K
2022-03-080.21-0.11165.00K127.00K
2021-11-10-0.05-0.10140.00K189.00K
2021-08-16-0.19-0.10109.00K91.05K
2021-05-20-0.43-0.12157.00K223.72K
2021-03-18-0.11-0.14221.00K—
2020-11-19-0.09-0.2050.00K69.75K
2020-08-20-0.17-0.1252.00K36.71K
2020-05-21-0.16—42.00K—
2020-03-26-0.26—102.00K—
2019-11-21-0.25-0.1560.00K49.50K
2019-08-20-0.12-0.2874.00K172.67K
2019-06-27-0.26———
2019-03-28-0.17-0.35500.00K—
2019-01-22-0.45-0.28500.00K311.11K
2018-08-20-120.31-0.08——
2018-06-29-0.32———
2018-03-31-0.36———
2017-09-30-0.31———
2017-06-30-0.19———
2017-03-31-0.61———
2016-12-31-0.10———

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-08-18Camisasca Riccardo PaoloOther0——
2026-08-07Malca YonatanBuy22.82K——
2026-08-07Taitel HayaBuy20.79K——
2026-08-07Ellis SeanBuy20.03K——
2026-08-07Ellis SeanBuy40.00K$1.3754.80K
2026-08-07Yaacov-Garbeli DanaBuy140.00K$1.37191.80K
2026-08-07Galitzer HillelBuy200.00K$1.37274.00K
2026-08-07Burshtein GregoryBuy180.00K$1.37246.60K
2026-08-07Toledano Miranda JayneBuy500.00K$1.37685.00K
2026-08-07Toledano Miranda JayneBuy200.00K$2.81562.00K
2026-08-07Germano Geno JBuy25.01K——
2026-08-07Germano Geno JBuy50.00K$1.3768.50K
2026-08-07Germano Geno JBuy43.01K$1.3758.93K
2026-07-14Toledano Miranda JayneBuy72.99K——
2026-07-14Toledano Miranda JayneBuy347.57K——
2026-05-07Galitzer HillelBuy72.99K——
2026-05-07Yaacov-Garbeli DanaBuy58.39K——
2026-05-07Burshtein GregoryBuy87.59K——
2026-03-09Germano Geno JBuy20.00K$1.3026.00K
2026-03-05Ellis SeanBuy10.00K$1.2312.30K
2026-02-10Taitel HayaBuy7.50K$1.4811.10K
2026-02-10Germano Geno JBuy20.00K$1.4929.80K
2026-02-09Ellis SeanBuy18.00K$1.2422.32K
2026-02-04Germano Geno JOther0——
2026-01-01OSTROV GERALD MBuy28.72K——
2026-01-01OSTROV GERALD MBuy33.51K$1.9465.00K
2026-01-01Ellis SeanBuy25.37K——
2026-01-01Ellis SeanBuy33.51K$1.9465.00K
2026-01-01Malca YonatanBuy30.16K——
2026-01-01Malca YonatanBuy33.51K$1.9465.00K
2026-01-01LIEBERMAN GERALD MBuy38.29K——
2026-01-01LIEBERMAN GERALD MBuy33.51K$1.9465.00K
2026-01-01Taitel HayaBuy26.33K——
2026-01-01Taitel HayaBuy33.51K$1.9465.00K
2025-12-29Toledano Miranda JayneBuy11.00K$1.8119.91K
2025-07-16Toledano Miranda JayneBuy500.00K$2.281.14M
2025-07-16Toledano Miranda JayneBuy43.86K——
2025-07-16Toledano Miranda JayneBuy136.84K——
2025-07-16Burshtein GregoryBuy200.00K$2.28456.00K
2025-07-16Burshtein GregoryBuy26.32K——
2025-07-16Yaacov-Garbeli DanaBuy130.00K$2.28296.40K
2025-07-16Yaacov-Garbeli DanaBuy26.32K——
2025-05-08Gautam Leslie VelkaOther60.00K$2.28136.80K
2025-04-28Galitzer HillelBuy100.00K$2.28228.00K
2025-04-28Galitzer HillelBuy26.32K——
2025-04-01LIEBERMAN GERALD MBuy23.95K$1.0023.95K
2025-04-01LIEBERMAN GERALD MSell23.95K$1.0023.95K
2025-01-15Taitel HayaBuy6.92K——
2025-01-15Taitel HayaBuy28.51K$2.2865.00K
2025-01-15OSTROV GERALD MBuy8.04K——
2025-01-15OSTROV GERALD MBuy28.51K$2.2865.00K
2025-01-15Malca YonatanBuy8.22K——
2025-01-15Malca YonatanBuy28.51K$2.2865.00K
2025-01-15LIEBERMAN GERALD MBuy10.72K——
2025-01-15LIEBERMAN GERALD MBuy28.51K$2.2865.00K
2025-01-15Ellis SeanBuy7.10K——
2025-01-15Ellis SeanBuy28.51K$2.2865.00K
2024-11-14Knoll Capital Management, LLCOther0——
2024-10-02Taitel HayaBuy7.28K——
2024-10-02OSTROV GERALD MBuy8.45K——
2024-10-02Malca YonatanBuy8.64K——
2024-10-02LIEBERMAN GERALD MBuy11.27K——
2024-10-02Ellis SeanBuy7.47K——
2024-08-27OSTROV GERALD MBuy20.45K——
2024-08-27Taitel HayaBuy15.34K——
2024-08-27Ellis SeanBuy18.06K——
2024-08-27Malca YonatanBuy23.17K——
2024-08-27LIEBERMAN GERALD MBuy27.26K——
2024-07-31Toledano Miranda JayneBuy500.00K$1.99995.00K
2024-07-31Toledano Miranda JayneBuy124.12K——
2024-05-28Burshtein GregorySell0——
2024-05-28Burshtein GregorySell45.00K$2.57115.65K
2024-05-28Burshtein GregorySell51.00K$3.61184.11K
2024-05-28Burshtein GregorySell65.00K$0.8051.67K
2024-05-28Burshtein GregorySell150.00K$1.99298.50K
2024-05-28Burshtein GregorySell18.90K$2.1440.45K
2024-05-28Burshtein GregorySell20.00K$3.9779.40K
2024-04-19Yaacov-Garbeli DanaBuy130.00K$1.99258.70K
2024-04-19Yaacov-Garbeli DanaBuy30.15K——
2024-04-19Galitzer HillelBuy130.00K$1.99258.70K
2024-04-19Galitzer HillelBuy30.15K——
2024-01-12Taitel HayaBuy9.50K$0.999.40K
2024-01-10Taitel HayaBuy7.62K$0.775.86K
2024-01-01Taitel HayaBuy108.33K$0.6065.00K
2024-01-01GARCEAU ROGERBuy108.33K$0.6065.00K
2024-01-01Malca YonatanBuy108.33K$0.6065.00K
2024-01-01OSTROV GERALD MBuy108.33K$0.6065.00K
2024-01-01Mayron RonBuy108.33K$0.6065.00K
2024-01-01LIEBERMAN GERALD MBuy108.33K$0.6065.00K
2024-01-01Ellis SeanBuy108.33K$0.6065.00K
2023-12-22Knoll Capital Management, LLCOther347.60K——
2023-12-22Knoll Capital Management, LLCOther1.20M$1.001.20M
2023-12-22LIEBERMAN GERALD MBuy23.95K$0.7117.01K
2023-12-22LIEBERMAN GERALD MBuy23.95K$1.0023.95K
2023-12-22Toledano Miranda JayneBuy23.95K$0.7117.01K
2023-12-22Toledano Miranda JayneBuy23.95K$1.0023.95K
2023-09-13Taitel HayaBuy33.37K$0.8126.99K
2023-09-13Toledano Miranda JayneBuy350.00K$0.80278.25K
2023-08-22Taitel HayaBuy18.00K$0.6211.22K
2023-08-21LIEBERMAN GERALD MBuy20.00K$0.5911.78K

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 28, holders +2 vs prior quarter. Ownership 21.27%.

HolderSharesChangeChange %Value
KNOLL CAPITAL MANAGEMENT, LLC5.88M00.00%10.41M
BVF INC/IL2.42M2.42MNew4.29M
SIREN, L.L.C.736.46K736.46KNew1.30M
RENAISSANCE TECHNOLOGIES LLC368.85K-104.59K-22.09%652.86K
PARKMAN HEALTHCARE PARTNERS LLC274.50K-14.17K-4.91%485.86K
PNC FINANCIAL SERVICES GROUP, INC.273.03K263.03K+2630.31%483.26K
SEVEN FLEET CAPITAL MANAGEMENT LP191.35K-14.19K-6.90%338.70K
HIGHTOWER ADVISORS, LLC74.57K37.74K+102.48%132.94K
HRT FINANCIAL LP72.49K56.99K+367.89%128.00K
SCHONFELD STRATEGIC ADVISORS LLC58.87K3.65K+6.61%104.20K
TWO SIGMA SECURITIES, LLC48.59K48.59KNew86.01K
SIGNATURE ESTATE & INVESTMENT ADVISORS LLC47.33K00.00%83.77K
CITADEL ADVISORS LLC38.80K-206.77K-84.20%68.68K
JPMORGAN CHASE & CO40.88K33.73K+471.79%67.46K
VIRTU FINANCIAL LLC36.92K36.92KNew65.00K
GEODE CAPITAL MANAGEMENT, LLC29.91K8.77K+41.50%52.94K
DIADEMA PARTNERS LP23.26K00.00%41.17K
XTX TOPCO LTD20.56K-111.06K-84.38%36.39K
GEM INVESTMENT ADVISORS, LLC19.14K00.00%33.87K
JANE STREET GROUP, LLC17.33K-15.58K-47.35%30.68K
SIMPLEX TRADING, LLC15.70K15.70KNew27.79K
SG AMERICAS SECURITIES, LLC13.91K13.91KNew25.00K
UBS GROUP AG12.72K9.51K+296.11%22.52K
CITADEL ADVISORS LLC10.10K-235.48K-95.89%17.88K
PERSISTENT ASSET PARTNERS LTD5.88K00.00%10.41K

Insights · Forecast · Financials · Learn

Stocklytics home · Screener

Entera Bio (ENTX) Stock Insights

ENTX$3.19+0.07 +2.24%

$554.81M

Market Cap

-8.94

P/E

—

Forward P/E

67

Score

AI Analysis

Snapshot

Loading market score…

Price History

Financial Summary

Entera Bio Ltd. (ENTX) trades at $3.19, with a market cap of $554.81M and a trailing P/E of -8.94. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.

Financials

2016201720182019202020212022202320242025
$0.00$0.00$500,000.00$236,000.00$365,000.00$571,000.00$134,000.00$0.00$181,000.00$42,000.00

About

Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.